AKOYA BIOSCIENCES INC (AKYA) Stock Price, Quote, News and Overview
NASDAQ:AKYA - Nasdaq - US00974H1041 - Common Stock - Currency: USD
AKYA Quote, Performance and Key Statistics
1.59
+0.03 (+1.92%)
The current stock price of AKYA is 1.59 USD. In the past month the price decreased by -36.65%. In the past year, price decreased by -68.2%.
AKYA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.32 | 200.59B | ||
| DHR | DANAHER CORP | 28.31 | 151.57B | ||
| A | AGILENT TECHNOLOGIES INC | 23.86 | 36.12B | ||
| IQV | IQVIA HOLDINGS INC | 17.2 | 33.79B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.38 | 27.02B | ||
| WAT | WATERS CORP | 33.11 | 23.35B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 34.29 | 16.74B | ||
| ICLR | ICON PLC | 13.33 | 15.40B | ||
| RVTY | REVVITY INC | 23.99 | 14.13B | ||
| ILMN | ILLUMINA INC | 35.36 | 13.72B | ||
| AVTR | AVANTOR INC | 17.5 | 11.92B | ||
| TECH | BIO-TECHNE CORP | 35.56 | 10.18B |
Related stock screener links
About AKYA
Company Profile
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 330 full-time employees. The company went IPO on 2021-04-16. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. The company offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).
Company Info
AKOYA BIOSCIENCES INC
100 Campus Drive, 6th Floor
Marlborough MASSACHUSETTS US
CEO: Brian McKelligon
Employees: 330
Company Website: https://www.akoyabio.com/
Investor Relations: http://investors.akoyabio.com
Phone: 18558968401
AKOYA BIOSCIENCES INC / AKYA FAQ
What is the stock price of AKOYA BIOSCIENCES INC today?
The current stock price of AKYA is 1.59 USD. The price increased by 1.92% in the last trading session.
What is the ticker symbol for AKOYA BIOSCIENCES INC stock?
The exchange symbol of AKOYA BIOSCIENCES INC is AKYA and it is listed on the Nasdaq exchange.
On which exchange is AKYA stock listed?
AKYA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AKOYA BIOSCIENCES INC stock?
14 analysts have analysed AKYA and the average price target is 3.67 USD. This implies a price increase of 130.94% is expected in the next year compared to the current price of 1.59. Check the AKOYA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AKOYA BIOSCIENCES INC worth?
AKOYA BIOSCIENCES INC (AKYA) has a market capitalization of 78.82M USD. This makes AKYA a Micro Cap stock.
How many employees does AKOYA BIOSCIENCES INC have?
AKOYA BIOSCIENCES INC (AKYA) currently has 330 employees.
What are the support and resistance levels for AKOYA BIOSCIENCES INC (AKYA) stock?
AKOYA BIOSCIENCES INC (AKYA) has a resistance level at 2.69. Check the full technical report for a detailed analysis of AKYA support and resistance levels.
Is AKOYA BIOSCIENCES INC (AKYA) expected to grow?
The Revenue of AKOYA BIOSCIENCES INC (AKYA) is expected to decline by -14.96% in the next year. Check the estimates tab for more information on the AKYA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AKOYA BIOSCIENCES INC (AKYA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AKYA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AKYA, evaluating the profitability, health, valuation and growth aspects
- AKOYA BIOSCIENCES INC (AKYA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AKOYA BIOSCIENCES INC (AKYA) Sales and EPS estimates to see what analysts future expectations are.
- AKOYA BIOSCIENCES INC (AKYA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AKOYA BIOSCIENCES INC (AKYA) Insider and Institutional Ownership to learn about the owners and their transactions.
- AKOYA BIOSCIENCES INC (AKYA) Stock Chart to make your own analysis
- AKOYA BIOSCIENCES INC (AKYA) Latest news and press-releases to stay up to date.
Does AKOYA BIOSCIENCES INC (AKYA) stock pay dividends?
AKYA does not pay a dividend.
When does AKOYA BIOSCIENCES INC (AKYA) report earnings?
AKOYA BIOSCIENCES INC (AKYA) will report earnings on 2025-03-10, after the market close.
What is the Price/Earnings (PE) ratio of AKOYA BIOSCIENCES INC (AKYA)?
AKOYA BIOSCIENCES INC (AKYA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.18).
AKYA Technical Analysis
AKYA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AKYA. AKYA has a bad profitability rating. Also its financial health evaluation is rather negative.
AKYA Financial Highlights
Over the last trailing twelve months AKYA reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 30.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.6% | ||
| ROE | -425.2% | ||
| Debt/Equity | 5.62 |
AKYA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 74% to AKYA. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 21.81% and a revenue growth -14.96% for AKYA